In TAM reprogramming strategies, shifting M2-like to M1-like phenotypes reprograms TAMs toward pro-inflammatory M1-like states via CD40 agonists, TLR activators, or radiotherapy, which showed anti-tumor effects in preclinical models [330]. This evidence concerns the gene CD40 and neoplasm.